CEVEC and CSL Limited sign exclusive license agreement for production of recombinant C1 Esterase Inhibitor using CEVEC’s proprietary CAP®Go technology
- CAP®Go provides unique opportunity for CSL to develop highly differentiated recombinant C1 Esterase Inhibitor (C1-IHN) proteins for Hereditary Angioedema (HAE) and other potential indications
- CSL to leverage CEVEC’s expertise in the production of C1-INH based on CAP®Go technology
- Further important step in establishing CAP®Go as the production standard for difficult to express recombinant proteins
Cologne, Germany and Melbourne, Australia, May 8, 2018
CEVEC Pharmaceuticals GmbH (CEVEC), the expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, and global biotechnology leader CSL Limited (ASX:CSL; USOTC:CSLLY) today announced an exclusive licensing agreement for the development, manufacture and commercialization of recombinant C1 Esterase Inhibitor (C1-INH) proteins for Hereditary Angioedema (HAE) and other potential indications using CEVEC’s proprietary CAP®Go technology.